A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.
about
Current Status of Gene Engineering Cell Therapeutics.Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.CD16NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted miceEvidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells
P2860
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A phase I trial of NK-92 cells ...... fety and evidence of efficacy.
@en
A phase I trial of NK-92 cells ...... fety and evidence of efficacy.
@nl
type
label
A phase I trial of NK-92 cells ...... fety and evidence of efficacy.
@en
A phase I trial of NK-92 cells ...... fety and evidence of efficacy.
@nl
prefLabel
A phase I trial of NK-92 cells ...... fety and evidence of efficacy.
@en
A phase I trial of NK-92 cells ...... fety and evidence of efficacy.
@nl
P2093
P2860
P356
P1433
P1476
A phase I trial of NK-92 cells ...... fety and evidence of efficacy.
@en
P2093
Amélie Chaboureau
Arjun Datt Law
Armand Keating
Bertrand Routy
Brent A Williams
Neal denHollander
Sowmya Viswanathan
Vikas Gupta
Xing-Hua Wang
P2860
P304
89256-89268
P356
10.18632/ONCOTARGET.19204
P407
P577
2017-07-12T00:00:00Z